Form 4: KalVista CEO Reports Future RSU Vesting and Tax Sale

KalVista Pharmaceuticals CEO Benjamin L. Palleiko reported future transactions under a Rule 10b5-1 plan, including RSU vesting and a subsequent stock sale for tax obligations.

Summary

• CEO Benjamin L. Palleiko reported transactions pursuant to a Rule 10b5-1 plan.
• On December 6, 2025, he is scheduled to acquire 15,625 shares of KalVista Pharmaceuticals common stock through the settlement of Restricted Stock Units (RSUs).
• Following this acquisition, his direct beneficial ownership of common stock is projected to be 431,814 shares.
• On December 8, 2025, he is scheduled to sell 7,294 shares of common stock at a price of $16.51 per share.
• This sale is designated as a "sell to cover" transaction to satisfy tax withholding obligations related to the RSU vesting and is not a discretionary transaction.
• After the scheduled sale, his direct beneficial ownership of common stock is projected to be 424,520 shares.
• He also holds 140,626 Restricted Stock Units directly, which vest quarterly.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction involving RSU vesting and a non-discretionary 'sell to cover' for tax purposes, pre-scheduled under a 10b5-1 plan, which is neutral in sentiment.

Positives

• The scheduled vesting of Restricted Stock Units indicates continued employment and performance-based compensation for the CEO.
• The transactions are pre-arranged under a Rule 10b5-1 plan, demonstrating a structured approach to insider stock transactions.

Negatives

• A projected reduction in direct common stock ownership due to the "sell to cover" transaction, although non-discretionary.

Future Outlook

The remaining 140,626 Restricted Stock Units will continue to vest quarterly, with 1/16th of the total number of shares subject to the RSU vesting on each quarterly anniversary of June 6, 2024, subject to Benjamin L. Palleiko's continued service.

Industry Context

NA

Stakeholder Impact

• Shareholders: A minor, non-discretionary reduction in the CEO's direct shareholding is projected, which is a common occurrence with RSU vesting and tax obligations.
• Employees: The vesting of RSUs demonstrates the company's compensation structure for executives.

Next Steps

• Continued quarterly vesting of the remaining 140,626 Restricted Stock Units, subject to Benjamin L. Palleiko's continued service.

Key Dates

Keywords

KalVista Pharmaceuticals, KALV, Benjamin L. Palleiko, CEO, Director, Form 4, Insider Trading, Stock Sale, RSU, Restricted Stock Units, Tax Withholding, Sell to Cover, Beneficial Ownership, Rule 10b5-1 Plan